Annual HVTN Translational HIV Early Stage Investigator (ESI) Conference

年度 HVTN 转化 HIV 早期研究者 (ESI) 会议

• 批准号: 10641676
• 负责人: James G. Kublin
• 金额: $ 7.5万
• 依托单位: FRED HUTCHINSON CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-04-07 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10641676
• 关键词: Acceleration; Acquired Immunodeficiency Syndrome; Address; Affect; Animal Model; Award; Career Choice; Childhood; Clinical Research; Clinical Trials; Clinical Trials Design; Collaborations; Communicable Diseases; Development; Disabled Persons; Disease; Disease remission; Eligibility Determination; Epidemic; Evaluation; Event; Funding; Grant; Group Meetings; HIV; HIV Vaccine Trials Network; HIV vaccine; HIV/AIDS; HIV/TB; Human; Individual; Infection; International; Intervention; Investments; Knowledge; Learning; Mentors; Modeling; Monoclonal Antibodies; Needs Assessment; Peer Review; Prevention; Prevention strategy; Primates; Process; Qualifying; Randomized; Reproducibility; Request for Applications; Research; Research Personnel; Resources; Role; Science; Scientist; Secure; Talents; Therapeutic; Training; Training Programs; Translating; Translational Research; Translations; Travel; Tuberculosis; Tuberculosis Vaccines; Underrepresented Minority; United States National Institutes of Health; Vaccines; Viral; Vision; Woman; Work; Workforce Development; Writing; antiretroviral therapy; career; career development; career networking; co-infection; comorbidity; cost; efficacy trial; empowerment; experimental study; innovation; meetings; multidisciplinary; nonhuman primate; novel; pandemic disease; peer; phase III trial; pre-clinical; preclinical study; prevent; programs; skill acquisition; skills; success; symposium; vaccine evaluation; vaccine-induced antibodies

PROJECT SUMMARY ANNUAL HVTN TRANSLATIONAL HIV EARLY STAGE INVESTIGATOR (ESI) CONFERENCE This R13 application requests continued NIH support for four annual conferences for Early Stage Investigators (ESIs) conducting translational HIV vaccine, co-morbidity, barrier to infection, and cure research with nonhuman primates (NHPs). The Conference offers an intimate setting where ESIs build skills, knowledge, professional networks and career development strategies with their peers and senior investigators in the field. Year 1 is proposed to take place September 28-29, 2020 in Portland, OR, immediately preceding the 38th NHP-AIDS Symposium, with complementary programming planned. Subsequent meetings will be adjacent to either the Symposium or HIV Vaccine Trials Network (HVTN) Full Group Meeting, allowing for additional opportunities for learning, training and networking. Conference topic selection will be guided by a needs assessment from K01 HIV/AIDS Scholars and mentors, an innovative practice used to great effect for the 2017-2019 Conferences. Agenda development and advising for these Conferences will be led by a diverse, multi-disciplinary group of experts in the fields at multiple stages in their careers. Attendees at the ESI Conferences will participate in training and skill-building activities on important translational scientific topics (e.g., state of prevention, vaccine, therapeutic and cure research; TB and coinfections in the NHP model); mentoring opportunities with senior and peer investigators (e.g., panel discussions on partnerships and career paths in the field); career development training (e.g., ESI funding landscape, how to conduct research with HVTN); “Works in Progress” presentations; and organized networking opportunities with other ESIs and senior investigators (e.g., receptions, randomized seating). We will fund attendance at these Conferences and the HVTN Full Group Meeting or NHP-AIDS Symposium for talented ESIs, with priority for underrepresented applicants, and K01 mentors, providing opportunities for these groups to continue to interact and support translational science. The Conference is open to all qualified investigators at no cost to attendees. Inclusion of women, underrepresented minorities and individuals with disabilities will be supported as speakers, attendees and advisors. The Conferences will be organized by staff at the HVTN, the world’s largest publicly funded collaboration facilitating the development and testing of vaccines to prevent HIV/AIDS. They will be housed within the existing HVTN Training Program, which has shown considerable success in supporting investigators at multiple career stages, and which organized highly meaningful and impactful ESI Conferences from 2017-2019. These conferences fill a critical gap in scientific knowledge and workforce development by facilitating greater translation of research between preclinical NHP studies and clinical trials, which will ultimately accelerate progress towards controlling the HIV epidemic and related co-infections in the coming decade.

项目概要 年度 HVTN 转化 HIV 早期研究者 (ESI) 会议 此 R13 申请要求 NIH 继续支持早期研究人员的四次年度会议 (ESI) 开展转化型 HIV 疫苗、共病、感染屏障和非人类治愈研究 灵长类动物 (NHP) 会议提供了一个亲密的环境，ESI 可以在这里培养技能、知识和专业知识。 第一年是与同行和该领域的高级研究人员的网络和职业发展策略。 建议于 2020 年 9 月 28 日至 29 日在俄勒冈州波特兰举行，紧接第 38 届 NHP-AIDS 大会之前 研讨会以及后续的会议安排将与任一会议相邻。 研讨会或 HIV 疫苗试验网络 (HVTN) 全体小组会议，为 学习、培训和交流的主题选择将以 K01 的需求评估为指导。 艾滋病毒/艾滋病学者和导师，这一创新实践对 2017-2019 年会议产生了巨大影响。 这些会议的议程制定和建议将由多元化、多学科的小组领导 ESI 会议的与会者将参加该领域多个职业阶段的专家。 关于重要转化科学主题（例如预防状况、疫苗、 治疗和治愈研究；NHP 模式中的结核病和合并感染）； 同行调查员（例如，关于该领域的伙伴关系和职业道路的小组讨论）； 培训（例如，ESI 资助情况、如何​​利用 HVTN 进行研究）； 并组织与其他 ESI 和高级研究人员的交流机会（例如招待会、随机 我们将资助参加这些会议和 HVTN 全体小组会议或 NHP-AIDS。 为有才华的 ESI 举办的研讨会，优先考虑代表性不足的申请者和 K01 导师，提供 这些团体有机会继续互动并支持转化科学。 向所有合格的调查人员开放，与会者无需支付任何费用。 残疾人士将作为演讲者、与会者和顾问得到支持。 由 HVTN 的工作人员组织，这是世界上最大的公共资助合作，促进发展和 预防艾滋病毒/艾滋病的疫苗测试将纳入现有的 HVTN 培训计划中。 在支持多个职业阶段的调查人员方面取得了相当大的成功，并组织了 2017-2019 年的 ESI 会议非常有意义和有影响力，这些会议填补了 2017 年的关键空白。 通过促进临床前研究的更大转化来促进科学知识和劳动力发展 NHP 研究和临床试验，最终将加速控制艾滋病毒流行的进展 以及未来十年的相关合并感染。